RASSURE - Virtual Reality to Soothe, Secure, Simulate Uses, and Successfully Complete the Examination (RASSURE)
Pilot Study Evaluating the Impact of Immersive Virtual Reality-Based Habituation to Medical Care Compared With Traditional Habituation to Medical Care on Anxiety Levels in People With Disabilities Receiving Care in a Dedicated Disability Consultation Setting
The RASSURE study aims to evaluate the effect of a preparation for care programme combining a traditional habituation method with a digital immersive virtual reality tool ('PREPASOINS_VR'), compared with traditional habituation alone. In particular, the study aims to measure the impact of the use of IVR on the anxiety experienced during the actual treatment, as well as on various indicators relating to the delivery of the treatment, its progress and the experience of the patients.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Aurélie Dr DURUFLE, Principal Investigator
- Telefonnummer: +33299295099
- E-Mail: aurelie.durufle@fondationsainthelier.com
Studienorte
-
-
-
Rennes, Frankreich
- Fondation Saint-Hélier
-
Kontakt:
- Aurélie DURUFLE
- Telefonnummer: +33299295099
- E-Mail: aurelie.durufle@fondationsainthelier.com
-
Thorigné-Fouillard, Frankreich
- MAS le Placis Vert - DAPAH - CHGR
-
Kontakt:
- CELINE BUCHAILLET
- Telefonnummer: 0223271133
- E-Mail: c.buchaillet@ch-guillaumeregnier.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Adults:
- Adults (age ≥ 18) at the time of enrollment
- Users of the Handi Accès 35 program who have experienced treatment failure in mainstream healthcare settings
- Individuals with a psychological or mental disability (e.g., autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down syndrome, cerebral palsy, etc.) that creates significant barriers to accessing care (e.g., failure to receive care, failure due to past experience (perceived/contact-related), refusal of care, architectural barriers, anticipated failure, lack of external care options) documented in the medical record
- Requiring a period of adjustment to care
- Having given free and informed consent
- Able to understand the French language (care acclimatization kits-available only in French)
- Enrolled in a social security program or eligible for an equivalent benefit
Minors:
- Children aged between 9 and 17 (inclusive) at the time of inclusion
- Users of the Handi Accès 35 scheme who have been unable to access care in mainstream settings
- People with a psychological or mental disability (for example: autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down's syndrome, cerebral palsy, etc.) which creates significant barriers to accessing care (e.g. failure to access care, failure due to experience (perception/interaction), refusal of treatment, architectural barriers, anticipated failure, no external care provision) documented in the medical record
- Requiring a period of adjustment to care
- Registered with a social security scheme or entitled to an equivalent benefit
- Able to understand French (care familiarisation kits - available in French only)
- Minors for whom free, informed and written consent has been obtained from both holders of parental authority or, in exceptional cases, from a single holder under the conditions set out in Article L1122-2 of the Public Health Code.
Caregivers:
- Adult: a person aged 18 or over
- Informed consent: voluntary agreement to participate in the study following a full explanation of its terms.
- Registered with a social security scheme or an eligible dependant
- Agree to and be able to carry out the treatment familiarisation process with their relative and to accompany them to the dedicated consultation
Exclusion Criteria:
-
majors : Participants requiring urgent medical care that prevents them from completing an 8-week familiarisation period with the treatment
- Participants at high risk of epileptic seizures, or with uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
- Individuals with visual impairments that make the use of VR impossible
- Individuals who refuse to wear the VR headset, in the investigator's judgement
- Pregnant or breastfeeding women
- Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
- Individuals in an emergency situation who are unable to give their prior consent.
minors : Individuals requiring urgent care that prevents them from completing an 8-week acclimatisation period
- Refusal expressed by the child, notwithstanding the prior consent of the parents or holders of parental authority
- Children subject to a court-ordered protection measure involving a specific placement, which is incompatible with participation in the study
- A person presenting a major risk of epileptic seizures, or uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
- A person with visual impairments that make the use of VR impossible
- A person refusing to wear the VR headset, in the investigator's judgement
- Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
- Individuals in an emergency situation who are unable to give their prior consent.
Caregiver: Vulnerable individuals referred to in Articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code are excluded from the study:
- Pregnant women, women in labour or breastfeeding women
- Persons deprived of their liberty by a judicial decision (including guardianship, curatorship and judicial protection) or an administrative decision
- Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research
- Persons in an emergency situation who are unable to give their prior consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Traditional treatment habituation method only
For each group, once they have been briefed, the following materials will be provided:
|
A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR). The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention. A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters. |
|
Experimental: Traditional care habituation combined with virtual reality
In addition to the traditional care habituation materials provided to participants in the control group, participants in this group will also receive:
The virtual reality programme includes eight care scenarios covering dental care, dental mobile unit visits, gynaecological and ophthalmological consultations, follow-up appointments for physical medicine and rehabilitation, somatic assessments, blood tests and electrocardiograms. |
A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR). The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention. A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters. An immersive virtual reality headset used with the PREPASOINS_VR solution. The device enables participants to view immersive 360-degree videos presenting different medical and care scenarios as part of the care familiarisation programme. It is used exclusively in the experimental group. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Skin Conductance (SC) During the Actual Treatment Procedure (µS)
Zeitfenster: At Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
Skin conductance (SC), expressed in microsiemens (µS), measured using an Empatica wristband during the actual treatment procedure at Visit 1. Skin conductance reflects changes in the electrical conductance of the skin associated with sweat secretion by the eccrine sweat glands, particularly those located on the palms and soles. Skin conductance is a physiological measure of electrodermal activity (EDA) associated with sympathetic nervous system activity. |
At Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change From Baseline in Caregiver-Reported Patient Anxiety Score on the Visual Analogue Scale at 2-3 Months
Zeitfenster: At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
|
Patient anxiety score as perceived and reported by the caregiver, measured using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates maximum anxiety. The assessment is performed at inclusion (baseline) and at Visit 1 (2-3 months after enrolment). The change in anxiety score between baseline and Visit 1 will be reported. Higher scores indicate higher levels of perceived anxiety (worse outcome). |
At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
|
|
Percentage of Care Provided During the Actual Treatment Procedure (%)
Zeitfenster: Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
The degree of care provision during the actual treatment procedure, assessed by the healthcare professional using a numerical scale ranging from 0% (care not provided) to 100% (care fully provided). Intermediate values indicate partial care provision. A derived categorical variable will also be reported, distinguishing complete care provision (100%) from incomplete care provision (partial care provision or no care provided). |
Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
|
Use of Premedication Before the Treatment Procedure (Yes/No)
Zeitfenster: At Visit 1 (between 2 and 3 months after enrolment).
|
Use of premedication before the actual treatment procedure, recorded as a binary variable (yes/no). When premedication is used, its type (pharmacological or non-pharmacological) will also be recorded. For pharmacological premedication, the medication name and dose will be documented, when applicable. |
At Visit 1 (between 2 and 3 months after enrolment).
|
|
Use and Acceptance of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA)
Zeitfenster: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Use of conscious sedation with nitrous oxide/oxygen (MEOPA) during the actual treatment procedure, recorded as a categorical variable: administered and accepted, refused, or not used. |
During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Duration of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA) (Minutes)
Zeitfenster: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Duration of MEOPA administration during the actual treatment procedure, measured in minutes among participants who receive conscious sedation. |
During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Number of Preparatory Visits Before the Actual Treatment Procedure
Zeitfenster: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Number of preparatory visits ("dry runs") completed before the actual treatment procedure. A preparatory visit is defined as a visit during which the patient attends the treatment setting but the planned treatment is not performed. The total number of preparatory visits completed before the actual treatment will be recorded. |
From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Pain Score During the Treatment Procedure Measured Using the Postoperative Pain Assessment Grid for Individuals with Intellectual Disabilities (GED-DI)
Zeitfenster: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
|
Pain experienced by the patient during the treatment procedure, measured using the Postoperative Version of the Pain Assessment Grid for Individuals with Intellectual Disabilities (Grille d'Évaluation de la Douleur - Déficience Intellectuelle, GED-DI). The scale consists of 27 behavioral items, each scored from 0 to 3, resulting in a total score ranging from 0 to 81. The scale is completed after the treatment by the healthcare professional who performed the procedure, with the assistance of a companion when necessary. Higher scores indicate greater pain intensity (worse outcome). Scores of 6-10 indicate mild pain, while scores of 11 or higher indicate moderate to severe pain. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
|
|
Caregiver Satisfaction With the Care Provided During the Treatment Procedure
Zeitfenster: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Caregiver satisfaction with the care provided during the actual treatment procedure, assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater satisfaction and a better outcome. The questionnaire is completed by the caregiver, if present during the consultation. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Healthcare Professional-Rated Ease of Performing the Treatment Procedure
Zeitfenster: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
The perceived ease of performing the actual treatment procedure, assessed by the healthcare professional using a 5-point Likert scale ranging from 1 (very difficult) to 5 (very easy). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater ease of performing the procedure and a better outcome. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Duration of the Treatment Habituation Period (Days)
Zeitfenster: From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Duration of the treatment habituation period, measured in days from the date of the first habituation session to the date of the actual treatment procedure. The duration is calculated as the number of calendar days between these two dates. |
From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Number of Treatment Habituation Sessions
Zeitfenster: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Total number of habituation sessions completed by each participant between enrolment and the actual treatment procedure. |
From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Recruitment Rate (%)
Zeitfenster: From the start of recruitment until the end of the recruitment period, up to 12 months
|
Proportion of eligible participants who agreed to participate and were enrolled in the study, calculated as the number of enrolled participants divided by the number of eligible participants approached, multiplied by 100. |
From the start of recruitment until the end of the recruitment period, up to 12 months
|
|
Recruitment Speed (Participants per Month)
Zeitfenster: Up to 12 months
|
Average number of participants enrolled per month during the recruitment period, calculated as the total number of enrolled participants divided by the number of months of active recruitment. |
Up to 12 months
|
|
Eligibility Rate (%)
Zeitfenster: Up to 12 months
|
Proportion of individuals assessed for eligibility who met all study eligibility criteria, calculated as the number of eligible individuals divided by the total number of individuals assessed for eligibility, multiplied by 100. |
Up to 12 months
|
|
participant Refusal Rate (%)
Zeitfenster: Up to 12 months
|
Proportion of individuals approached for study participation who declined to participate, calculated as the number of individuals who refused participation divided by the total number of individuals approached, multiplied by 100. |
Up to 12 months
|
|
Intervention Adherence Rate (%)
Zeitfenster: From enrolment up to Visit 1, up to 3 months
|
Proportion of enrolled participants who completed at least two treatment habituation sessions, calculated as the number of participants completing at least two sessions divided by the total number of enrolled participants, multiplied by 100. |
From enrolment up to Visit 1, up to 3 months
|
|
Acceptance Rate of the Dummy Wristband (%)
Zeitfenster: During the habituation period prior to Visit 1, up to 3 months post-enrolment
|
Proportion of participants who accepted wearing the dummy wristband, calculated as the number of participants who accepted wearing the dummy wristband divided by the total number of participants offered the dummy wristband, multiplied by 100. |
During the habituation period prior to Visit 1, up to 3 months post-enrolment
|
|
Acceptance Rate of the Embrace Plus Wristband on the Treatment Day (%)
Zeitfenster: At Visit 1, up to 3 months post-enrolment
|
Proportion of participants who accepted wearing the Embrace Plus wristband during the actual treatment procedure, calculated as the number of participants who accepted wearing the wristband divided by the total number of participants offered the wristband, multiplied by 100. |
At Visit 1, up to 3 months post-enrolment
|
|
Main Reasons for Non-Participation
Zeitfenster: Up to 12 months
|
Main reasons reported by individuals who declined participation in the study, recorded as categorical data. |
Up to 12 months
|
|
Time Interval Between Initial Contact and Study Inclusion (Days)
Zeitfenster: From initial contact until study inclusion, up to 12 months
|
Time interval, measured in calendar days, between the date of initial contact with the potential participant and the date of study inclusion. |
From initial contact until study inclusion, up to 12 months
|
|
Participant Follow-up Completion Rate (%)
Zeitfenster: From enrolment until Visit 1 (2-3 months after enrolment).
|
Proportion of enrolled participants who completed the planned study follow-up assessment at Visit 1, calculated as the number of participants completing Visit 1 divided by the total number of enrolled participants, multiplied by 100 |
From enrolment until Visit 1 (2-3 months after enrolment).
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2026-A01473-48
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .